Use of in vitro OmniPlex libraries for high-throughput comparative genomics and molecular haplotyping

OmniPlex Technology is a new approach to genome amplification and targeted analysis. Initially the entire genome is reformatted into small, amplifiable molecules called Plexisomes, which represent the entire genome as an OmniPlex Library. The whole genome can be amplified en masse using universal primers; using locus-specific primers, regions as large as 50 kb can be amplified. Amplified Plexisomes can be analyzed using conventional methods such as capillary sequencing and microarray hybridization. The advantages to using OmniPlex as the 'front-end' for conventional analytical instruments are that a) the initial copy number of the analytes can be increased to achieve better signal-to-noire ratio, b) only a single priming site is used and c) up to 20 times fewer biochemical reactions and oligonucleotides are necessary to amplify a large region, compared to conventional PCR. These factors make OmniPlex more flexible, faster, and less expensive than conventional technologies. OmniPlex has been applied to targeted sequencing of human, animal, plant, and microorganism genomes. In addition, OmniPlex is inherently able to haplotype large regions of human DNA to accelerate target discovery and pharmacogenomics. OmniPlex will be a key tool for delivery of improved crops and livestock, new pharmaceutical products, and personalized medicine.

[1]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R Judson,et al.  Notes from the SNP vs. haplotype front. , 2001, Pharmacogenomics.

[3]  K. Kidd,et al.  Direct haplotyping of chromosomal segments from multiple heterozygotes via allele-specific PCR amplification. , 1989, Nucleic acids research.

[4]  M. Boehnke,et al.  Experimentally-derived haplotypes substantially increase the efficiency of linkage disequilibrium studies , 2001, Nature Genetics.

[5]  K K Kidd,et al.  Haplotype of multiple polymorphisms resolved by enzymatic amplification of single DNA molecules. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Kidd,et al.  Genotyping and haplotyping of polymorphisms directly from genomic DNA via coupled amplification and sequencing (CAS). , 1991, Nucleic acids research.

[7]  D. Goldstein.  Islands of linkage disequilibrium , 2001, Nature Genetics.

[8]  M. Daly,et al.  High-resolution haplotype structure in the human genome , 2001, Nature Genetics.

[9]  B. G. Rothberg,et al.  Mapping a role for SNPs in drug development , 2001, Nature Biotechnology.

[10]  Pardis C Sabeti,et al.  Linkage disequilibrium in the human genome , 2001, Nature.

[11]  A. Jeffreys,et al.  Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex , 2001, Nature Genetics.

[12]  Jason Lazarou,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 1999 .

[13]  Sinead B. O'Leary,et al.  Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease , 2001, Nature Genetics.

[14]  K K Kidd,et al.  Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. , 2000, Human molecular genetics.

[15]  W. Evans,et al.  Pharmacogenetics as a Molecular Basis for Individualized Drug Therapy: The Thiopurine S-methyltransferase Paradigm , 1999, Pharmaceutical Research.